Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
JNJ-42165279
Cat. No.:
OB0225LY-0487
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
JNJ-42165279 is a small molecule compound that acts as a targeted drug for diabetes and metabolic diseases.
Synonym:
JNJ42165279; 1346528-50-4; N-(4-Chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxamide; N-(4-Chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide; N-(4-Chloropyridin-3-yl)-4-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
CAS No.:
1346528-50-4
Compound CID:
54576693
Formula:
C18H17ClF2N4O3
Formula Weight:
410.8
Specification
Relative Density:
1.52 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
JNJ-42165279 can be used to study metabolic regulation mechanisms or play an important role in studies of anti-obesity drug development.
Library Information
Targets:
FAAH
Receptors:
hFAAH; rFAAH
Pathways:
Neuronal signaling; Autophagy; Metabolism
Plate Number:
AOCL-7
Plate Location:
c7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
45 mg/mL; 109.54 mM
